Therapeutic potential of dendritic cell vaccines in sarcoma of the extremities

References

• Ordóñez JL, Martins AS, Osuna D, Madoz-Gúrpide J, de Alava E. Targeting sarcomas: therapeutic targets and their rational. Semin. Diagn. Pathol.25(4), 304–316 (2008).
   PubMedGoogle Scholar
• Weber K, Damron TA, Frassica FJ, Sim FH. Malignant bone tumors. Instr. Course Lect.57, 673–688 (2008).
   PubMedGoogle Scholar
• Todd R, Lunec J. Molecular pathology and potential therapeutic targets in soft-tissue sarcoma. Expert Rev. Anticancer Ther.8(6), 939–948 (2008).
   PubMed Web of Science ®Google Scholar
• Muraro M, Mereuta OM, Saglio F et al. Interactions between osteosarcoma cell lines and dendritic cells immune function: an in vitro study. Cell Immunol.253(1–2), 71–80 (2008).
   PubMedGoogle Scholar
• Soilleux EJ, Rous B, Love K et al. Myxofibrosarcomas contain large numbers of infiltrating immature dendritic cells. Am. J. Clin. Pathol.119(4), 540–545 (2003).
   PubMedGoogle Scholar
• Orui H, Ishikawa A, Okada K et al. Dendritic cell and effector cell infiltration in soft tissue sarcomas with reactive lymphoid hyperplasia. J. Orthop Sci.8(5), 669–677 (2003).
   PubMedGoogle Scholar
• Maki RG. Future directions for immunotherapeutic intervention against sarcomas. Curr. Opin. Oncol.18(4), 363–368 (2006).
   PubMedGoogle Scholar
• Lin ML, Zhan Y, Villadangos JA, Lew AM. The cell biology of cross-presentation and the role of dendritic cell subsets. Immunol. Cell Biol.86(4), 353–362 (2008).
   PubMed Web of Science ®Google Scholar
• Shin JY, Lee SK, Kang CD et al. Antitumor effect of intratumoral administration of dendritic cell combination with vincristine chemotherapy in a murine fibrosarcoma model. Histol. Histopathol.18(2), 435–447 (2003).
   PubMed Web of Science ®Google Scholar
• Tanaka F, Hashimoto W, Robbins PD, Lotze MT, Tahara H. Therapeutic and specific anti-tumor immunity induced by co-administration of immature dendritic cells and adenoviral vector expressing biologically active IL-18. Gene Ther.9(21), 1480–1486 (2002).
   PubMed Web of Science ®Google Scholar
• Tanaka F, Hashimoto W, Okamura H, Robbins PD, Lotze MT, Tahara H. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells. Cancer Res.60(17), 4838–4844 (2000).
   PubMed Web of Science ®Google Scholar
• Marcove RC, Southam CM, Levin A, Mike V, Huvos A. A clinical trial of autogenous vaccine in osteogenic sarcoma in patients under the age of twenty-five. Surg. Forum22, 434–435 (1971).
   PubMedGoogle Scholar
• Matsuzaki A, Suminoe A, Hattori H, Hoshina T, Hara T. Immunotherapy with autologous dendritic cells and tumor-specific synthetic peptides for synovial sarcoma. J. Pediatr. Hematol. Oncol.24(3), 220–223 (2002).
   PubMed Web of Science ®Google Scholar
• Bercovici N, Haicheur N, Massicard S et al. Analysis and characterization of anti-tumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients. J. Immunother.31(1), 101–112 (2008).
   PubMedGoogle Scholar
• Palucka AK, Ueno H, Connolly J et al. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J. Immunother.29(5), 545–557 (2006).
   PubMed Web of Science ®Google Scholar
• Gong J, Koido S, Calderwood SK. Cell fusion: from hybridoma to dendritic cell-based vaccine. Expert Rev. Vaccines7(7), 1055–1068 (2008).
   PubMed Web of Science ®Google Scholar
• Tabarkiewicz J, Radej S, Hus I et al. Dendritic cells based immunotherapy of patient with chondrosarcoma – case report. Folia Histochem. Cytobiol.46(2), 165–170 (2008).
   PubMedGoogle Scholar
• Dagher R, Long LM, Read EJ et al. Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study. Med. Pediatr. Oncol.38(3), 158–164 (2002).
   PubMedGoogle Scholar
• Di Nicola M, Zappasodi R, Carlo-Stella C et al. Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study. Blood113(1), 18–27 (2009).
   PubMed Web of Science ®Google Scholar
• Camilo C. DC–tumour fusions: every which way but allo. Trends Immunol.23(11), 521–522 (2002).
   Google Scholar
• Yu Z, Ma B, Zhou Y, Zhang M, Qiu X, Fan Q. Activation of anti-tumor cytotoxic T lymphocytes by fusion of patient-derived dendritic cells with autologous osteosarcoma. Exp. Oncol.27(4), 273–278 (2005).
   PubMed Web of Science ®Google Scholar
• Yu Z, Ma B, Zhou Y et al. Allogeneic tumor vaccine produced by electrofusion between osteosarcoma cell line and dendritic cells in the induction of anti-tumor immunity. Cancer Invest.25(7), 535–541 (2007).
   PubMed Web of Science ®Google Scholar
• Yu Z, Sun H, Fan Q, Long H, Yang T, Ma B. Establishment of reproducible osteosarcoma rat model using orthotopic implantation technique. Oncol. Rep.21(5), 1175–1180 (2009).
   PubMedGoogle Scholar
• Yu Z, Fan Q, Hao X, Long H. Specific anti-tumor effects of tumor vaccine produced by electrofusion between osteosarcoma cell and dendritic cell in rats. Cell Mol. Immunol.1(6), 454–460 (2004).
   PubMedGoogle Scholar
• Yu Z, Sun H, Zhang T, Yang T, Long H, Ma B. Specific anti-tumor effects of tumor vaccine produced by autologous dendritic cells transfected with allogeneic osteosarcoma total RNA through electroporation in rats. Cancer Biol. Ther.8(10), 94–102 (2009).
   PubMedGoogle Scholar
• Guo W, Guo Y, Tang S, Qu H, Zhao H. Dendritic cell–Ewing’s sarcoma cell hybrids enhance anti-tumor immunity. Clin. Orthop. Relat. Res.466(9), 2176–2183 (2008).
   PubMedGoogle Scholar
• Tatsumi T, Gambotto A, Robbins PD, Storkus WJ. Interleukin 18 gene transfer expands the repertoire of anti-tumor Th1-type immunity elicited by dendritic cell-based vaccines in association with enhanced therapeutic efficacy. Cancer Res.62(20), 5853–5858 (2002).
   PubMed Web of Science ®Google Scholar
• Ogawa F, Iinuma H, Okinaga K. Dendritic cell vaccine therapy by immunization with fusion cells of interleukin-2 gene-transduced, spleen-derived dendritic cells and tumor cells. Scand. J. Immunol.59(5), 432–439 (2004).
   PubMed Web of Science ®Google Scholar
• Chauvin C, Philippeau JM, Hémont C et al. Killer dendritic cells link innate and adaptive immunity against established osteosarcoma in rats. Cancer Res.68(22), 9433–9440 (2008).
   PubMed Web of Science ®Google Scholar
• Wongkajornsilp A, Sangsuriyong S, Hongeng S, Waikakul S, Asavamongkolkul A, Huabprasert S. Effective osteosarcoma cytolysis using cytokine-induced killer cells pre-inoculated with tumor RNA-pulsed dendritic cells. J. Orthop. Res.23(6), 1460–1466 (2005).
   PubMed Web of Science ®Google Scholar
• Zeelenberg IS, Ostrowski M, Krumeich S et al. Targeting tumor antigens to secreted membrane vesicles in vivo induces efficient anti-tumor immune responses. Cancer Res.68(4), 1228–1235 (2008).
   PubMed Web of Science ®Google Scholar
• Riley LB, Agarwala SS. Melanoma vaccines. Expert Rev. Vaccines7(7), 937–949 (2008).
   PubMed Web of Science ®Google Scholar
• Lehrfeld TJ, Lee DI. Dendritic cell vaccines for the treatment of prostate cancer. Urol. Oncol.26(6), 576–580 (2008).
   PubMedGoogle Scholar
• Gong J, Nikrui N, Chen D et al. Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce anti-tumor immunity. J. Immunol.165(3), 1705–1711 (2000).
   PubMed Web of Science ®Google Scholar
• Chan RC, Xie H, Zhao GP, Xie Y. Dendritomas formed by fusion of mature dendritic cells with allogenic human hepatocellular carcinoma cells activate autologous cytotoxic T lymphocytes. Immunol. Lett.83(2), 101–109 (2002).
   PubMedGoogle Scholar
• Schadendorf D, Ugurel S, Schuler-Thurner B et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized Phase III trial of the DC study group of the DeCOG. Ann. Oncol.17(4), 563–570 (2006).
   PubMed Web of Science ®Google Scholar
• Melief CJ. Cancer immunotherapy by dendritic cells. Immunity29(3), 372–383 (2008).
   PubMed Web of Science ®Google Scholar
• Clarkson P, Ferguson PC. Management of soft tissue sarcomas of the extremities. Expert Rev. Anticancer Ther.4(2), 237–246 (2004).
   PubMedGoogle Scholar